How Anne Wojcicki Built 23andMe Through Regulatory Chaos

Episode notes

Episode 43 of The CEO Diary with Fexingo takes you inside the rollercoaster ride of Anne Wojcicki and 23andMe. Starting in 2006, Wojcicki set out to democratize genetic testing, selling $99 saliva kits directly to consumers. But in 2013, the FDA slammed the door, ordering the company to stop marketing health reports. Lucas and Luna break down how Wojcicki navigated the multi-year regulatory battle, kept the company alive through sheer grit and a pivot to ancestry data, and eventually won FDA approval for genetic health risk reports in 2017. They explore the hard choices: laying off half the staff, losing key partnerships, and the controversial decision to sell raw data to pharma. A masterclass in resilience and regulatory strategy for any founder facing government scrutiny. #AnneWojcicki #23andMe #DirectToConsumer #FDA #GeneticTesting #RegulatoryStrategy #Biotech #Startup #Resilience #ConsumerGenomics #HealthTech #Business #CEOInterview #Leadership #FexingoBusiness #BusinessPodcast #CornerOffice #FounderStory Keep every episode free: buymeacoffee.com/fexingo